PRITHVIRAJBOSEPRITHVIRAJ BOSE11923BOSE, PRITHVIRAJAssistant Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonExperimental TherapeuticsLeukemiaMD AndersonVARSHA VGANDHIVARSHA V GANDHI8582GANDHI, VARSHA VProfessorJORGE ECORTESJORGE E CORTES8637CORTES, JORGE EProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorSRDANVERSTOVSEKSRDAN VERSTOVSEK8781VERSTOVSEK, SRDANProfessorMARINAKONOPLEVAMARINA KONOPLEVA8702KONOPLEVA, MARINAProfessorGUILLERMOGARCIA-MANEROGUILLERMO GARCIA-MANERO8853GARCIA-MANERO, GUILLERMOProfessorNAVEENPEMMARAJUNAVEEN PEMMARAJU9516PEMMARAJU, NAVEENAssistant Professor74Professor10Assistant Professor1400 Holcombe BlvdHouston77030-4008TX10.55310.0129941398research areas23.33050.037942281coauthor of1194.133160similar to11187selected publicationsAuthorship 372817119484732Bose P, Hussein KK, Terrell DR, Berger D, Rice L, George JNAmerican journal of hematologySuccessful treatment of cyclic thrombocytopenia with thrombopoietin-mimetic agents: a report of two patients. Am J Hematol. 2009 Jul; 84(7):459-61.Am J Hematol2009-07-01T00:00:002009Successful treatment of cyclic thrombocytopenia with thrombopoietin-mimetic agents: a report of two patients.Authorship 841964Authorship 843255Authorship 843616Authorship 847181Authorship 848046Authorship 850371Authorship 852361Authorship 853918Authorship 854387Authorship 854448Authorship 855873Authorship 856523Authorship 857639Authorship 857671Authorship 859048Authorship 859316Authorship 860159Authorship 864517Authorship 864953Authorship 865139Authorship 867781Pharmacology and TherapeuticsHistone deacetylase inhibitor (HDACI) mechanisms of action. Pharmacology and Therapeutics. 143:323-336.Histone deacetylase inhibitor (HDACI) mechanisms of actionCan we cure CML without transplantation?. 279-326.Can we cure CML without transplantation?Leukemia Research ReportsMcl-1 as a therapeutic target in acute myelogenous leukemia (AML). Leukemia Research Reports. 2:12-14.Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML)Leukemia and LymphomaClinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leukemia and Lymphoma. 1-6.Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical studyClinical Lymphoma, Myeloma and LeukemiaPrognosis of Primary Myelofibrosis in the Genomic Era. Clinical Lymphoma, Myeloma and Leukemia. 16:S105-S113.Prognosis of Primary Myelofibrosis in the Genomic EraClinical Cancer ResearchA Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an oral MEK1/2 inhibitor, in relapsed/refractory multiple myeloma. Clinical Cancer Research. 22:1067-1075.A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an oral MEK1/2 inhibitor, in relapsed/refractory multiple myelomaCore EvidenceRasburicase in the management of tumor lysis. Core Evidence. 10:23-38.Rasburicase in the management of tumor lysisExpert Opinion on PharmacotherapyMyelofibrosis. Expert Opinion on Pharmacotherapy. 17:2375-2389.MyelofibrosisBcl-2 family. 151-173.Bcl-2 familyLeukemiaDecrease in total protein level of bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes. Leukemia. 30:1803-1804.Decrease in total protein level of bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytesExpert Opinion on Drug Metabolism and ToxicologyPharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia. Expert Opinion on Drug Metabolism and Toxicology. 1-12.Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemiaEmerging therapeutic options for metastatic exocrine pancreatic cancer. 159-172.Emerging therapeutic options for metastatic exocrine pancreatic cancerSummary of treatment and recommended follow-up of CML patients. 183-190.Summary of treatment and recommended follow-up of CML patientsLeukemia and LymphomaPhase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. Leukemia and Lymphoma. Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomasExpert Opinion on Investigational DrugsInvestigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms. Expert Opinion on Investigational Drugs. 25:1393-1403.Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasmsCancerThe evolution and clinical relevance of prognostic classification systems in myelofibrosis. Cancer. 122:681-692.The evolution and clinical relevance of prognostic classification systems in myelofibrosisNew England Journal of MedicineThe authors reply. New England Journal of Medicine. 361:931-932.The authors replyThe Lancet HaematologyRuxolitinib for symptom control in patients with chronic lymphocytic leukaemia. The Lancet Haematology. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemiaJNCCN Journal of the National Comprehensive Cancer NetworkDrug development pipeline for myeloproliferative neoplasms. JNCCN Journal of the National Comprehensive Cancer Network. 14:1613-1624.Drug development pipeline for myeloproliferative neoplasmsHaematologicaRandomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 100:1172-1179.Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemiaLeukemia Research ReportsStrategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase. Leukemia Research Reports. 2:18-20.Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinaseD055728Disorders1248310.54942Primary MyelofibrosisD009196Disorders1397660.579171Myeloproliferative DisordersD011087Disorders472380.795318Polycythemia VeraAuthorship 8993041Authorship 8996341Authorship 9001411Authorship 9005301Authorship 9010641Authorship 9010963Authorship 9018551Authorship 9021172Authorship 9022304Authorship 9027822Authorship 9031791Authorship 9035461Authorship 9036475Authorship 9057402Authorship 9058412Authorship 9064084Authorship 9064631Authorship 9072774Authorship 9082891Authorship 9084948Authorship 9096151Authorship 9097001Authorship 9102673Authorship 9123281Authorship 9131211Authorship 9138272Authorship 9144381Authorship 9148203Authorship 9152311Authorship 9159701Authorship 9163971Authorship 9171391Authorship 9176521Authorship 9188017Authorship 9192909Authorship 9214803Authorship 9216611Authorship 9217202Authorship 9217431Authorship 9217954Authorship 9226041Authorship 92299521Authorship 9233411Authorship 9237241Authorship 9241143Authorship 92439511Authorship 92557414Authorship 9259485Authorship 92609410D053614Chemicals & Drugs1666790.711224Janus Kinase 2Authorship 9281431Authorship 9282266Authorship 9298641Authorship 9302298Authorship 9302866Authorship 9310431Authorship 9311678Authorship 93570115Authorship 9358059Authorship 9368217Authorship 93811214Authorship 9381523Authorship 9397391Authorship 9397576Authorship 9398791Authorship 940093819220417Bose P, Thompson C, Gandhi D, Ghabach B, Ozer HEuropean journal of haematologyAIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib. Eur J Haematol. 2009 Jun; 82(6):490-2.Eur J Haematol2009-02-05T00:00:002009AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib.19780706Bose P, Ozer HExpert opinion on investigational drugsNeratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert Opin Investig Drugs. 2009 Nov; 18(11):1735-51.Expert Opin Investig Drugs2009-11-01T00:00:002009Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer.21115932Bose P, Dunn ST, Yang J, Allen R, El-Khoury C, Tfayli AAnticancer researchc-Kit expression and mutations in phyllodes tumors of the breast. Anticancer Res. 2010 Nov; 30(11):4731-6.Anticancer Res2010-11-01T00:00:002010c-Kit expression and mutations in phyllodes tumors of the breast.22349810Bose P, Perkins EB, Honeycut C, Wellons MD, Stefan T, Jacobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Douglas Figg W, Karp JE, Koc ON, Cooper BW, Luger SM, Colevas AD, Roberts JD, Grant SCancer chemotherapy and pharmacologyPhase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies. Cancer Chemother Pharmacol. 2012 Jun; 69(6):1657-67.Cancer Chemother Pharmacol2012-02-15T00:00:002012Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.23647051Bose P, Simmons GL, Grant SExpert opinion on investigational drugsCyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs. 2013 Jun; 22(6):723-38.Expert Opin Investig Drugs2013-05-06T00:00:002013Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.23439314Bose P, Rahmani M, Grant SOncotargetCoordinate PI3K pathway and Bcl-2 family disruption in AML. Oncotarget. 2012 Dec; 3(12):1499-500.Oncotarget2012-12-01T00:00:002012Coordinate PI3K pathway and Bcl-2 family disruption in AML.23489225Skiver BM, Patel SB, Bose PEuropean journal of haematologyIt is not always immune thrombocytopenia: a case of MYH9-related platelet disorder caused by a novel mutation. Eur J Haematol. 2013 Aug; 91(2):191-2.Eur J Haematol2013-04-17T00:00:002013It is not always immune thrombocytopenia: a case of MYH9-related platelet disorder caused by a novel mutation.24769080Bose P, Dai Y, Grant SPharmacology & therapeuticsHistone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther. 2014 Sep; 143(3):323-36.Pharmacol Ther2014-04-24T00:00:002014Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.24824212Vachhani P, Bose P, Rahmani M, Grant SPhysiological genomicsRational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML. Physiol Genomics. 2014 Jul 01; 46(13):448-56.Physiol Genomics2014-05-13T00:00:002014Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.24996975Bose P, Grant SLeukemia researchOrphan drug designation for pracinostat, volasertib and alvocidib in AML. Leuk Res. 2014 Aug; 38(8):862-5.Leuk Res2014-06-17T00:00:002014Orphan drug designation for pracinostat, volasertib and alvocidib in AML.25105036Vachhani P, Bose PCase reports in hematologyIsolated gastric myeloid sarcoma: a case report and review of the literature. Case Rep Hematol. 2014; 2014:541807.Case Rep Hematol2014-07-06T00:00:002014Isolated gastric myeloid sarcoma: a case report and review of the literature.25263936Bose P, Batalo MS, Holkova B, Grant SExpert opinion on pharmacotherapyBortezomib for the treatment of non-Hodgkin's lymphoma. Expert Opin Pharmacother. 2014 Nov; 15(16):2443-59.Expert Opin Pharmacother2014-09-29T00:00:002014Bortezomib for the treatment of non-Hodgkin's lymphoma.25239883Vachhani P, Bose N, Brodeur JP, Holkova B, Bose PRheumatology (Oxford, England)Remission of rheumatoid arthritis on brentuximab vedotin. Rheumatology (Oxford). 2014 Dec; 53(12):2314-5.Rheumatology (Oxford)2014-09-18T00:00:002014Remission of rheumatoid arthritis on brentuximab vedotin.25248382Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, Roberts JD, Sullivan D, Grant SClinical cancer research : an official journal of the American Association for Cancer ResearchPhase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res. 2014 Nov 15; 20(22):5652-62.Clin Cancer Res2014-09-23T00:00:002014Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.26284612Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, Shrader E, Weir-Wiggins C, Rollins AD, Cebula EM, Pierce E, Herr M, Sankala H, Hogan KT, Wan W, Feng C, Peterson DR, Fisher RI, Grant S, Friedberg JWLeukemia & lymphomaPhase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. Leuk Lymphoma. 2016; 57(3):635-43.Leuk Lymphoma2015-10-12T00:00:002015Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.26022709Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JEHaematologicaRandomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep; 100(9):1172-9.Haematologica2015-05-28T00:00:002015Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.26446942Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann M, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala H, Hogan KT, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan D, Landgren O, Grant SClinical cancer research : an official journal of the American Association for Cancer ResearchA Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2016 Mar 01; 22(5):1067-75.Clin Cancer Res2015-10-07T00:00:002015A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.26717494Bose P, Verstovsek SCancerThe evolution and clinical relevance of prognostic classification systems in myelofibrosis. Cancer. 2016 Mar 01; 122(5):681-92.Cancer2015-12-30T00:00:002015The evolution and clinical relevance of prognostic classification systems in myelofibrosis.27521306Bose P, Verstovsek SClinical lymphoma, myeloma & leukemiaPrognosis of Primary Myelofibrosis in the Genomic Era. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S105-13.Clin Lymphoma Myeloma Leuk2016-08-01T00:00:002016Prognosis of Primary Myelofibrosis in the Genomic Era.27494751Naqvi K, Daver N, Pemmaraju N, Bose P, Garcia-Manero G, Cortes J, Kantarjian HM, Verstovsek SLeukemia & lymphomaClinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leuk Lymphoma. 2017 04; 58(4):866-871.Leuk Lymphoma2016-08-05T00:00:002016Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.27756180Bose P, Verstovsek SExpert opinion on investigational drugsInvestigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms. Expert Opin Investig Drugs. 2016 Dec; 25(12):1393-1403.Expert Opin Investig Drugs2016-10-31T00:00:002016Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.27984634Falchi L, Bose P, Newberry KJ, Verstovsek SBritish journal of haematologyApproach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment? Br J Haematol. 2017 Feb; 176(3):352-364.Br J Haematol2016-12-16T00:00:002016Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?28140720Bose P, Gandhi V, Konopleva MLeukemia & lymphomaPathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017 09; 58(9):1-17.Leuk Lymphoma2017-01-31T00:00:002017Pathways and mechanisms of venetoclax resistance.27956543Bose P, Verstovsek SJournal of the National Comprehensive Cancer Network : JNCCNDrug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management. J Natl Compr Canc Netw. 2016 12; 14(12):1613-1624.J Natl Compr Canc Netw2016-12-01T00:00:002016Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management.28130399Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O'Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov ZMolecular cancer research : MCRConstitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res. 2017 05; 15(5):610-618.Mol Cancer Res2017-01-27T00:00:002017Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex.27774820Bose P, Verstovsek SExpert opinion on pharmacotherapyMyelofibrosis: an update on drug therapy in 2016. Expert Opin Pharmacother. 2016 Dec; 17(18):2375-2389.Expert Opin Pharmacother2016-11-07T00:00:002016Myelofibrosis: an update on drug therapy in 2016.28103725Holkova B, Yazbeck V, Kmieciak M, Bose P, Ma S, Kimball A, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Singh A, Hogan KT, Conine S, Sankala H, Roberts JD, Shea TC, Grant SLeukemia & lymphomaA phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leuk Lymphoma. 2017 06; 58(6):1349-1357.Leuk Lymphoma2017-01-19T00:00:002017A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.27686109Bose P, Gandhi VV, Keating MJExpert opinion on drug metabolism & toxicologyPharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. Expert Opin Drug Metab Toxicol. 2016 Nov; 12(11):1381-1392.Expert Opin Drug Metab Toxicol2016-10-11T00:00:002016Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.28089238Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov ZThe Lancet. HaematologyRuxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017 Feb; 4(2):e67-e74.Lancet Haematol2017-01-12T00:00:002017Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial.28324773Strati P, Masarova L, Bose P, Daver N, Pemmaraju N, Verstovsek SLeukemia researchHaptoglobin is frequently low in patients with myelofibrosis: Clinical relevance. Leuk Res. 2017 06; 57:85-88.Leuk Res2017-03-08T00:00:002017Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance.28380402Boddu P, Falchi L, Hosing C, Newberry K, Bose P, Verstovsek SLeukemia researchThe role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review. Leuk Res. 2017 07; 58:14-22.Leuk Res2017-03-22T00:00:002017The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review.28441920Bose P, Abou Zahr A, Verstovsek SExpert opinion on investigational drugsInvestigational Janus kinase inhibitors in development for myelofibrosis. Expert Opin Investig Drugs. 2017 Jun; 26(6):723-734.Expert Opin Investig Drugs2017-05-08T00:00:002017Investigational Janus kinase inhibitors in development for myelofibrosis.28500170Bose P, Verstovsek SBloodJAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood. 2017 07 13; 130(2):115-125.Blood2017-05-12T00:00:002017JAK2 inhibitors for myeloproliferative neoplasms: what is next?28601551Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek SLeukemia researchPatients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res. 2017 08; 59:110-116.Leuk Res2017-06-02T00:00:002017Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.28247057Strati P, Bose P, Lyle L, Gaw K, Zhou L, Pierce SA, Huynh-Lu J, Hirsch-Ginsberg CF, Bueso-Mendoza DE, Bueso-Ramos CE, Verstovsek SAnnals of hematologyNovel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions. Ann Hematol. 2017 May; 96(5):733-738.Ann Hematol2017-02-28T00:00:002017Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions.28286924Bose P, Vachhani P, Cortes JECurrent treatment options in oncologyTreatment of Relapsed/Refractory Acute Myeloid Leukemia. Curr Treat Options Oncol. 2017 03; 18(3):17.Curr Treat Options Oncol2017-03-01T00:00:002017Treatment of Relapsed/Refractory Acute Myeloid Leukemia.28446054Abou Zahr A, Bose P, Keating MJExpert opinion on pharmacotherapyPharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. Expert Opin Pharmacother. 2017 Jun; 18(9):857-873.Expert Opin Pharmacother2017-05-16T00:00:002017Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.28674026Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver N, Cortes J, Kantarjian H, Verstovsek SBloodClonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017 08 31; 130(9):1125-1131.Blood2017-07-03T00:00:002017Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.29134664Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver NAmerican journal of hematologyA phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285.Am J Hematol2017-11-27T00:00:002017A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.28760302Bose P, Verstovsek SClinical lymphoma, myeloma & leukemiaDevelopmental Therapeutics in Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2017 07; 17S:S43-S52.Clin Lymphoma Myeloma Leuk2017-07-01T00:00:002017Developmental Therapeutics in Myeloproliferative Neoplasms.29047158Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi FAmerican journal of hematologyHyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2018 01; 93(1):91-99.Am J Hematol2017-11-03T00:00:002017Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.29375856Alhuraiji A, Naqvi K, Huh YO, Ho C, Verstovsek S, Bose PClinical case reportsAcute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure. Clin Case Rep. 2018 01; 6(1):155-161.Clin Case Rep2017-12-06T00:00:002017Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure.29533778Bose P, Konopleva MYCancer cellORY-1001: Overcoming the Differentiation Block in AML. Cancer Cell. 2018 03 12; 33(3):342-343.Cancer Cell2018-03-12T00:00:002018ORY-1001: Overcoming the Differentiation Block in AML.29226426Masarova L, Alhuraiji A, Bose P, Daver N, Pemmaraju N, Cortes J, Pierce S, Kantarjian H, Verstovsek SEuropean journal of haematologySignificance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol. 2018 Mar; 100(3):257-263.Eur J Haematol2018-01-17T00:00:002018Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.29723397Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HMCancerEarly results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018 07 01; 124(13):2740-2747.Cancer2018-05-03T00:00:002018Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.29152232Bose P, Gandhi VF1000ResearchRecent therapeutic advances in chronic lymphocytic leukemia. F1000Res. 2017; 6:1924.F1000Res2017-10-31T00:00:002017Recent therapeutic advances in chronic lymphocytic leukemia.29217697Bose P, Konopleva MYBloodT-PLL: another check on the venetoclax list? Blood. 2017 12 07; 130(23):2447-2448.Blood2017-12-07T00:00:002017T-PLL: another check on the venetoclax list?29277359Bose P, Gotlib J, Harrison CN, Verstovsek SClinical lymphoma, myeloma & leukemiaSOHO State-of-the-Art Update and Next Questions: MPN. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):1-12.Clin Lymphoma Myeloma Leuk2018-01-01T00:00:002018SOHO State-of-the-Art Update and Next Questions: MPN.29344542Bose P, Verstovsek SOncoscienceRuxolitinib for essential thrombocythemia? Oncoscience. 2017 Nov; 4(11-12):148-149.Oncoscience2017-11-01T00:00:002017Ruxolitinib for essential thrombocythemia?29415577Bose P, Swaminathan MCurrent medical research and opinionJanus kinase inhibition and symptom control in myeloproliferative neoplasms. Curr Med Res Opin. 2018 05; 34(5):935-937.Curr Med Res Opin2018-03-12T00:00:002018Janus kinase inhibition and symptom control in myeloproliferative neoplasms.29557496Khan M, Muzzafar T, Kantarjian H, Badar I, Short N, Wang X, Chamoun K, Jain P, DiNardo C, Pemmaraju N, Bose P, Borthakur G, Cortes J, Verstovsek S, Garcia-Manero G, Estrov ZAnnals of hematologyAssociation of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol. 2018 Jul; 97(7):1183-1191.Ann Hematol2018-03-20T00:00:002018Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.30118897Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JELeukemia researchFinal results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7?+?3) in newly diagnosed high-risk acute myeloid leukemia (AML). Leuk Res. 2018 09; 72:92-95.Leuk Res2018-08-10T00:00:002018Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7?+?3) in newly diagnosed high-risk acute myeloid leukemia (AML).30122201Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, Roberts JD, Sullivan D, Grant S, Holkova BClinical lymphoma, myeloma & leukemiaA Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2018 09; 18(9):569-575.e1.Clin Lymphoma Myeloma Leuk2018-06-06T00:00:002018A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.30328139Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero GAmerican journal of hematologyA phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol. 2019 01; 94(1):74-79.Am J Hematol2018-11-15T00:00:002018A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.29796726Bose P, Verstovsek SCurrent hematologic malignancy reportsManagement of Myelofibrosis-Related Cytopenias. Curr Hematol Malig Rep. 2018 06; 13(3):164-172.Curr Hematol Malig Rep2018-06-01T00:00:002018Management of Myelofibrosis-Related Cytopenias.30319961Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva MFrontiers in oncologyInitial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2018; 8:369.Front Oncol2018-09-24T00:00:002018Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.29771293Rausch CR, DiPippo AJ, Bose P, Kontoyiannis DPClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaBreakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole. Clin Infect Dis. 2018 10 30; 67(10):1610-1613.Clin Infect Dis2018-10-30T00:00:002018Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole.30575820Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KNLeukemiaTargeting nuclear ?-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia. 2019 06; 33(6):1373-1386.Leukemia2018-12-21T00:00:002018Targeting nuclear ?-catenin as therapy for post-myeloproliferative neoplasm secondary AML.30647404Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KNBlood cancer journalSuperior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J. 2019 01 15; 9(2):4.Blood Cancer J2019-01-15T00:00:002019Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells.30724681Bose P, Chen LS, Gandhi VLeukemia & lymphomaIbrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'. Leuk Lymphoma. 2019 07; 60(7):1603-1605.Leuk Lymphoma2019-02-06T00:00:002019Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'.30632841Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek SLeukemia & lymphomaA phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma. 2019 07; 60(7):1767-1774.Leuk Lymphoma2019-01-11T00:00:002019A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis.30635233Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi FClinical lymphoma, myeloma & leukemiaPhase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019 03; 19(3):142-148.e1.Clin Lymphoma Myeloma Leuk2018-12-20T00:00:002018Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.30545576Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi FThe Lancet. HaematologyTreatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019 Jan; 6(1):e29-e37.Lancet Haematol2018-12-10T00:00:002018Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.30545997Gotlib J, Gerds AT, Bose P, Castells MC, Deininger MW, Gojo I, Gundabolu K, Hobbs G, Jamieson C, McMahon B, Mohan SR, Oehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardanani A, Podoltsev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Thota S, Wadleigh M, Walsh K, Bergman MA, Sundar HJournal of the National Comprehensive Cancer Network : JNCCNSystemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 12; 16(12):1500-1537.J Natl Compr Canc Netw2018-12-01T00:00:002018Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.30675650Bose P, Alfayez M, Verstovsek SCurrent treatment options in oncologyNew Concepts of Treatment for Patients with Myelofibrosis. Curr Treat Options Oncol. 2019 01 24; 20(1):5.Curr Treat Options Oncol2019-01-24T00:00:002019New Concepts of Treatment for Patients with Myelofibrosis.D013920Disorders451620.846739Thrombocythemia, EssentialAuthorship 941160430811597Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek SCancerJanus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer. 2019 06 01; 125(11):1855-1866.Cancer2019-02-27T00:00:002019Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.30924136Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WGBritish journal of haematologyRoutine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol. 2019 06; 185(5):852-864.Br J Haematol2019-03-28T00:00:002019Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.Authorship 9436002Authorship 9438271Authorship 944127530254130Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, Jain N, Wierda WG, Keating MJ, Gandhi VBloodA pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018 11 22; 132(21):2249-2259.Blood2018-09-25T00:00:002018A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.30242087Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek SBloodMutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. Blood. 2018 11 08; 132(19):2100-2103.Blood2018-09-21T00:00:002018Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable.30185431Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver NBloodA phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.Blood2018-09-05T00:00:002018A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.Authorship 945817731013548Mughal TI, Pemmaraju N, Radich JP, Deininger MW, Kucine N, Kiladjian JJ, Bose P, Gotlib J, Valent P, Chen CC, Barbui T, Rampal R, Verstovsek S, Koschmieder S, Saglio G, Van Etten RAHematological oncologyEmerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. Hematol Oncol. 2019 Aug; 37(3):240-252.Hematol Oncol2019-06-20T00:00:002019Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms.Authorship 9471949Authorship 9479701531080940Numan Y, Alfayez M, Maiti A, Alvarado Y, Jabbour EJ, Ferrajoli A, Konoplev SN, Kantarjian HM, Bose PJCO precision oncologyFirst report of clinical response to Venetoclax in Early T-cell Precursor Acute Lymphoblastic Leukemia. JCO Precis Oncol. 2018; 2.JCO Precis Oncol2018-08-22T00:00:002018First report of clinical response to Venetoclax in Early T-cell Precursor Acute Lymphoblastic Leukemia.31141631Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WThe New England journal of medicineIbrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103.N Engl J Med2019-05-30T00:00:002019Ibrutinib and Venetoclax for First-Line Treatment of CLL.Authorship 949770231228096Masarova L, Bose P, Verstovsek SCurrent hematologic malignancy reportsThe Rationale for Immunotherapy in Myeloproliferative Neoplasms. Curr Hematol Malig Rep. 2019 08; 14(4):310-327.Curr Hematol Malig Rep2019-08-01T00:00:002019The Rationale for Immunotherapy in Myeloproliferative Neoplasms.Authorship 95058715Authorship 9507081931243771Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WGBritish journal of haematologyAssociation of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol. 2019 11; 187(3):307-318.Br J Haematol2019-06-26T00:00:002019Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients.31237017Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras Gonz?lez GM, Konopleva M, Andreeff M, Cortes J, Ravandi FAmerican journal of hematologyPrognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol. 2019 09; 94(9):984-991.Am J Hematol2019-06-24T00:00:002019Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.Authorship 951733731296578Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat URHaematologicaMixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica. 2021 07 01; 106(7):1988-1990.Haematologica2021-07-01T00:00:002021Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation.Authorship 9520891431310323Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi FCancerSorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer. 2019 Nov 01; 125(21):3755-3766.Cancer2019-07-16T00:00:002019Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.Authorship 95233620Authorship 9526128Authorship 952697931344256Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WGBritish journal of haematologyThe landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol. 2019 10; 187(1):e1-e4.Br J Haematol2019-07-25T00:00:002019The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype.31350306Gotlib J, Baird JH, George TI, Langford C, Reyes I, Abuel J, Perkins C, Schroeder K, Bose P, Verstovsek SBlood advancesA phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. Blood Adv. 2019 08 13; 3(15):2264-2271.Blood Adv2019-08-13T00:00:002019A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.Authorship 955467131516686Bose P, Verstovsek STherapeutic advances in hematologyUpdates in the management of polycythemia vera and essential thrombocythemia. Ther Adv Hematol. 2019; 10:2040620719870052.Ther Adv Hematol2019-08-30T00:00:002019Updates in the management of polycythemia vera and essential thrombocythemia.Authorship 956003831553487Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HMCancerLong-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020 01 01; 126(1):67-75.Cancer2019-09-25T00:00:002019Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.Authorship 956958131597841Bose P, Masarova L, Verstovsek S[Rinsho ketsueki] The Japanese journal of clinical hematologyNovel treatment strategies for myeloproliferative neoplasms. Rinsho Ketsueki. 2019; 60(9):1176-1185.Rinsho Ketsueki2019-01-01T00:00:002019Novel treatment strategies for myeloproliferative neoplasms.Authorship 9575391Authorship 957768831630335Bose P, Verstovsek SInternational journal of hematologyMutational profiling in myelofibrosis: implications for management. Int J Hematol. 2020 Feb; 111(2):192-199.Int J Hematol2019-10-19T00:00:002019Mutational profiling in myelofibrosis: implications for management.31645416Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Uziel O, Keating MJ, Estrov ZJournal of immunology (Baltimore, Md. : 1950)STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. J Immunol. 2019 12 01; 203(11):3078-3085.J Immunol2019-10-23T00:00:002019STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage.Authorship 9604681931682008Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour EAmerican journal of hematologyThe early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020 02; 95(2):144-150.Am J Hematol2019-11-19T00:00:002019The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.Authorship 975199123146050Bose P, Grant SExpert review of hematologyComplementary combinations: what treatments will become key to the battle against acute myelogenous leukemia? Expert Rev Hematol. 2012 Oct; 5(5):475-8.Expert Rev Hematol2012-10-01T00:00:002012Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia?Authorship 977704632035785Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y, Rytting M, Kebriaei P, Konopleva M, Kantarjian H, Ravandi FClinical lymphoma, myeloma & leukemiaClinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2020 04; 20(4):212-218.Clin Lymphoma Myeloma Leuk2019-09-30T00:00:002019Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.32068780Saenz DT, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury JD, Takahashi K, Bhaskara S, Lin CY, Green MR, Coarfa C, Crews CM, Verstovsek S, Bhalla KNBloodMechanistic basis and efficacy of targeting the ?-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Blood. 2020 04 09; 135(15):1255-1269.Blood2020-04-09T00:00:002020Mechanistic basis and efficacy of targeting the ?-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.Authorship 978523132099037Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi FLeukemiaA phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020 09; 34(9):2489-2492.Leukemia2020-02-25T00:00:002020A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia.Authorship 9788395Authorship 978875831305287Gordon SW, McGuire WP, Shafer DA, Sterling RK, Lee HM, Matherly SC, Roberts JD, Bose P, Tombes MB, Shrader EE, Ryan AA, Kmieciak M, Nguyen T, Deng X, Bandyopadhyay D, Dent P, Poklepovic ASAmerican journal of clinical oncologyPhase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. Am J Clin Oncol. 2019 08; 42(8):649-654.Am J Clin Oncol2019-08-01T00:00:002019Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma.27213589Poklepovic A, Gordon S, Shafer DA, Roberts JD, Bose P, Geyer CE, McGuire WP, Tombes MB, Shrader E, Strickler K, Quigley M, Wan W, Kmieciak M, Massey HD, Booth L, Moran RG, Dent POncotargetPhase I study of pemetrexed with sorafenib in advanced solid tumors. Oncotarget. 2016 07 05; 7(27):42625-42638.Oncotarget2016-07-05T00:00:002016Phase I study of pemetrexed with sorafenib in advanced solid tumors.Authorship 986256132236406Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Estrov Z, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DPClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaIsavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. Clin Infect Dis. 2021 05 18; 72(10):1755-1763.Clin Infect Dis2021-05-18T00:00:002021Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.Authorship 98645510Authorship 987464132297800Bose P, Verstovsek SLeukemia & lymphomaManagement of myelofibrosis after ruxolitinib failure. Leuk Lymphoma. 2020 08; 61(8):1797-1809.Leuk Lymphoma2020-04-16T00:00:002020Management of myelofibrosis after ruxolitinib failure.Authorship 988672832366832Samra B, Richard-Carpentier G, Kadia TM, Ravandi F, Daver N, DiNardo CD, Issa GC, Bose P, Konopleva MY, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes JE, Kantarjian H, Short NJBlood cancer journalCharacteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J. 2020 05 04; 10(5):47.Blood Cancer J2020-05-04T00:00:002020Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype.Authorship 99202610Authorship 992791532546726Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JELeukemiaPhase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924.Leukemia2020-06-16T00:00:002020Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality.32592408Mughal TI, Pemmaraju N, Psaila B, Radich J, Bose P, Lion T, Kiladjian JJ, Rampal R, Jain T, Verstovsek S, Yacoub A, Cortes JE, Mesa R, Saglio G, van Etten RAHematological oncologyIlluminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. Hematol Oncol. 2020 Dec; 38(5):654-664.Hematol Oncol2020-09-04T00:00:002020Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies.Authorship 9949872Authorship 995033232693648Chifotides HT, Bose P, Verstovsek SExpert opinion on investigational drugsGivinostat: an emerging treatment for polycythemia vera. Expert Opin Investig Drugs. 2020 Jun; 29(6):525-536.Expert Opin Investig Drugs2020-07-21T00:00:002020Givinostat: an emerging treatment for polycythemia vera.32697338Masarova L, Bose P, Pemmaraju N, Daver NG, Zhou L, Pierce S, Sasaki K, Kantarjian HM, Estrov Z, Verstovsek SCancerPrognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer. 2020 10 01; 126(19):4322-4331.Cancer2020-07-22T00:00:002020Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era.Authorship 9983253Authorship 998410132862851Bose PClinical lymphoma, myeloma & leukemiaA Young Woman with Thrombocytosis. Clin Lymphoma Myeloma Leuk. 2020 09; 20 Suppl 1:S14-S17.Clin Lymphoma Myeloma Leuk2020-09-01T00:00:002020A Young Woman with Thrombocytosis.32886902Gerds AT, Gotlib J, Bose P, Deininger MW, Dunbar A, Elshoury A, George TI, Gojo I, Gundabolu K, Hexner E, Hobbs G, Jain T, Jamieson C, Kuykendall AT, McMahon B, Mohan SR, Oehler V, Oh S, Pardanani A, Podoltsev N, Ranheim E, Rein L, Salit R, Snyder DS, Stein BL, Talpaz M, Thota S, Vachhani P, Wadleigh M, Walsh K, Ward DC, Bergman MA, Sundar HJournal of the National Comprehensive Cancer Network : JNCCNMyeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 09; 18(9):1248-1269.J Natl Compr Canc Netw2020-09-01T00:00:002020Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.Authorship 99914915Authorship 999213132896301DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MYThe Lancet. Haematology10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736.Lancet Haematol2020-09-05T00:00:00202010-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.32903304Bose P, Verstovsek SHemaSphereJAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives. Hemasphere. 2020 Aug; 4(4):e424.Hemasphere2020-07-21T00:00:002020JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives.Authorship 1002769133050168Bose P, Masarova L, Verstovsek SCancersNovel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms. Cancers (Basel). 2020 Oct 09; 12(10).Cancers (Basel)2020-10-09T00:00:002020Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms.Authorship 1003368133094033Bose PExpert opinion on orphan drugsAdvances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis. Expert Opin Orphan Drugs. 2019; 7(10):415-425.Expert Opin Orphan Drugs2019-09-24T00:00:002019Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis.Authorship 10056281133232476Gerds AT, Savona MR, Scott BL, Talpaz M, Egyed M, Harrison CN, Yacoub A, Vannucchi A, Mead AJ, Kiladjian JJ, O'Sullivan J, Garc?a-Guti?rrez V, Bose P, Rampal RK, Miller CB, Palmer J, Oh ST, Buckley SA, Mould DR, Ito K, Tyavanagimatt S, Smith JA, Roman-Torres K, Devineni S, Craig AR, Mascarenhas JOBlood advancesDetermining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Adv. 2020 11 24; 4(22):5825-5835.Blood Adv2020-11-24T00:00:002020Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.Authorship 10062412233264443Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MYAmerican journal of hematologyVenetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021 03 01; 96(3):282-291.Am J Hematol2020-12-24T00:00:002020Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.Authorship 1007696533356689Holkova B, Shafer D, Yazbeck V, Dave S, Bose P, Tombes MB, Shrader E, Wan W, Bandyopadhyay D, Weir C, Collins EB, Garnett A, Kmieciak M, Roberts JD, Garcia-Manero G, Grant SLeukemia & lymphomaPhase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome. Leuk Lymphoma. 2021 05; 62(5):1187-1194.Leuk Lymphoma2020-12-28T00:00:002020Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome.Authorship 10108672Authorship 1011062933563904Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MYBlood cancer journalTriplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J. 2021 02 01; 11(2):25.Blood Cancer J2021-02-01T00:00:002021Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.33551345Masarova L, Bose P, Pemmaraju N, Daver N, Zhou L, Pierce S, Kantarjian H, Estrov Z, Verstovsek SClinical lymphoma, myeloma & leukemiaClinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clin Lymphoma Myeloma Leuk. 2021 05; 21(5):318-327.e6.Clin Lymphoma Myeloma Leuk2021-01-06T00:00:002021Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy.Authorship 1013793133718939Bose P, Gandhi VFaculty reviewsManaging chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors. Fac Rev. 2021; 10:22.Fac Rev2021-02-26T00:00:002021Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors.Authorship 1014306933747356Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov ZOncotargetSTAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget. 2021 Mar 02; 12(5):401-411.Oncotarget2021-03-02T00:00:002021STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells.Authorship 10150687Authorship 101564211Authorship 10158821633821472Shah MV, Saliba RM, Varma A, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Masarova L, Alousi AM, Srour S, Mehta RS, Daver N, Pemmaraju N, Verstovsek S, Champlin RE, Popat URBritish journal of haematologyAllogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol. 2021 06; 193(5):1004-1008.Br J Haematol2021-04-06T00:00:002021Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era.33792630Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi FBlood advancesPrognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021 04 13; 5(7):1876-1883.Blood Adv2021-04-13T00:00:002021Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia.33811786Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, Daver N, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero GAmerican journal of hematologyClinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol. 2021 07 01; 96(7):E246-E249.Am J Hematol2021-04-24T00:00:002021Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS).Authorship 10167713Authorship 1016807333885751Masarova L, DiNardo CD, Bose P, Pemmaraju N, Daver NG, Kadia TM, Chifotides HT, Zhou L, Borthakur G, Estrov Z, Konopleva M, Verstovsek SBlood advancesSingle-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv. 2021 04 27; 5(8):2156-2164.Blood Adv2021-04-27T00:00:002021Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs.33882481Shahin OA, Chifotides HT, Bose P, Masarova L, Verstovsek SActa haematologicaAccelerated Phase of Myeloproliferative Neoplasms. Acta Haematol. 2021; 144(5):484-499.Acta Haematol2021-04-21T00:00:002021Accelerated Phase of Myeloproliferative Neoplasms.Authorship 10172752433914911Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero GCancerClinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 09 01; 127(17):3113-3124.Cancer2021-04-29T00:00:002021Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia.Authorship 1018453433990705Tang G, Tam W, Short NJ, Bose P, Wu D, Hurwitz SN, Bagg A, Rogers HJ, Hsi ED, Quesada AE, Wang W, Miranda RN, Bueso-Ramos CE, Medeiros LJ, Nardi V, Hasserjian RP, Arber DA, Orazi A, Foucar K, Wang SAModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncMyeloid/lymphoid neoplasms with FLT3 rearrangement. Mod Pathol. 2021 09; 34(9):1673-1685.Mod Pathol2021-05-14T00:00:002021Myeloid/lymphoid neoplasms with FLT3 rearrangement.Authorship 10188888Authorship 10190231234007049Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WGLeukemiaIbrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429.Leukemia2021-05-18T00:00:002021Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.34016956Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KNBlood cancer journalSuperior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J. 2021 05 20; 11(5):98.Blood Cancer J2021-05-20T00:00:002021Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells.Authorship 10207781634110383Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WGJAMA oncologyIbrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219.JAMA Oncol2021-08-01T00:00:002021Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.Authorship 1025276134272171Bose P, Verstovsek SClinical lymphoma, myeloma & leukemiaSOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2021 10; 21(10):641-649.Clin Lymphoma Myeloma Leuk2021-06-23T00:00:002021SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.Authorship 1025823134289787Bose P, Verstovsek SExpert review of hematologyAvapritinib for Systemic Mastocytosis. Expert Rev Hematol. 2021 08; 14(8):687-696.Expert Rev Hematol2021-08-06T00:00:002021Avapritinib for Systemic Mastocytosis.Authorship 10270841334340254Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero GBritish journal of haematologyPhase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol. 2021 11; 195(3):378-387.Br J Haematol2021-08-02T00:00:002021Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome.Authorship 1028234334424319Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek SBlood advancesFinal results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 2021 08 24; 5(16):3163-3173.Blood Adv2021-08-24T00:00:002021Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis.Authorship 1034107134775887Bose P, Mesa RALeukemia & lymphomaNovel strategies for challenging scenarios encountered in managing myelofibrosis. Leuk Lymphoma. 2022 04; 63(4):774-788.Leuk Lymphoma2021-11-15T00:00:002021Novel strategies for challenging scenarios encountered in managing myelofibrosis.Authorship 1034567234840087Chifotides HT, Bose P, Masarova L, Pemmaraju N, Verstovsek SClinical lymphoma, myeloma & leukemiaSOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2022 04; 22(4):210-223.Clin Lymphoma Myeloma Leuk2021-10-13T00:00:002021SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis.Authorship 103502716Authorship 1035029734873345Gotlib J, Reiter A, Radia DH, Deininger MW, George TI, Panse J, Vannucchi AM, Platzbecker U, Alvarez-Twose I, Mital A, Hermine O, Dybedal I, Hexner EO, Hicks LK, Span L, Mesa R, Bose P, Pettit KM, Heaney ML, Oh ST, Sen J, Lin HM, Mar BG, DeAngelo DJNature medicineEfficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med. 2021 12; 27(12):2192-2199.Nat Med2021-12-06T00:00:002021Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.34873347DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, Bose P, Hexner EO, Winton EF, Horny HP, Tugnait M, Schmidt-Kittler O, Evans EK, Lin HM, Mar BG, Verstovsek S, Deininger MW, Gotlib JNature medicineSafety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021 12; 27(12):2183-2191.Nat Med2021-12-06T00:00:002021Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.Authorship 10386261Authorship 10390283Authorship 10392146Authorship 10398234Authorship 10401182Authorship 1040519235309812Bose P, Verstovsek SHemaSphereMF management. Hemasphere. 2019 Jun; 3(Suppl).Hemasphere2019-06-30T00:00:002019MF management.35084934Vachhani P, Verstovsek S, Bose PJournal of clinical oncology : official journal of the American Society of Clinical OncologyDisease Modification in Myelofibrosis: An Elusive Goal? J Clin Oncol. 2022 04 10; 40(11):1147-1154.J Clin Oncol2022-01-27T00:00:002022Disease Modification in Myelofibrosis: An Elusive Goal?35102145Fiskus W, Manshouri T, Birdwell C, Mill CP, Masarova L, Bose P, Kadia TM, Daver N, DiNardo CD, Borthakur G, Khoury JD, Verstovsek S, Bhalla KNBlood cancer journalEfficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Blood Cancer J. 2022 01 31; 12(1):23.Blood Cancer J2022-01-31T00:00:002022Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells.35077575Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek SCancerImproved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer. 2022 04 15; 128(8):1658-1665.Cancer2022-01-25T00:00:002022Improved survival of patients with myelofibrosis in the last decade: Single-center experience.35153007Pasca S, Chifotides HT, Verstovsek S, Bose PInternational review of cell and molecular biologyMutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN. Int Rev Cell Mol Biol. 2022; 366:83-124.Int Rev Cell Mol Biol2021-12-14T00:00:002021Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.35045875Chifotides HT, Bose P, Verstovsek SJournal of hematology & oncologyMomelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol. 2022 01 19; 15(1):7.J Hematol Oncol2022-01-19T00:00:002022Momelotinib: an emerging treatment for myelofibrosis patients with anemia.Authorship 1043277535368098Mughal TI, Pemmaraju N, Bejar R, Gale RP, Bose P, Kiladjian JJ, Prchal J, Royston D, Pollyea D, Valent P, Br?mmendorf TH, Skorski T, Patnaik M, Santini V, Fenaux P, Kucine N, Verstovsek S, Mesa R, Barbui T, Saglio G, Van Etten RAHematological oncologyPerspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. Hematol Oncol. 2022 Oct; 40(4):491-504.Hematol Oncol2022-04-15T00:00:002022Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies.Authorship 10462851035595309Rozovski U, Veletic I, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov ZJournal of immunology (Baltimore, Md. : 1950)STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol. 2022 06 15; 208(12):2847-2855.J Immunol2022-05-20T00:00:002022STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells.Authorship 10479441335690645Tashakori M, Khoury JD, Routbort MJ, Patel KP, Wang SA, Ok CY, El-Hussein S, Kanagal-Shamanna R, Luthra R, Hu S, Lin P, Pemmaraju N, Bose P, Verstovsek S, Bueso-Ramos CE, Medeiros LJ, Loghavi SModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncClinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol. 2022 11; 35(11):1677-1683.Mod Pathol2022-06-11T00:00:002022Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations.Authorship 10497581135787095Senapati J, Verstovsek S, Masarova L, Pemmaraju N, Patel KP, Montalban-Bravo G, Pierce SA, Zhou L, Garcia-Manero G, Kantarjian HM, Bose PLeukemia & lymphomaImpact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma. 2022 11; 63(11):2701-2705.Leuk Lymphoma2022-07-05T00:00:002022Impact of SF3B1 mutation in myelofibrosis.Authorship 10573233Authorship 10581864Authorship 10574759Authorship 10550122Authorship 10589581Authorship 10546332836054032Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian HAmerican journal of hematologyLow-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol. 2022 Nov; 97(11):1413-1418.Am J Hematol2022-08-27T00:00:002022Low-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.36125942Bose PClinical advances in hematology & oncology : H&OCases in the management of polycythemia vera: a patient with progressive leukocytosis. Clin Adv Hematol Oncol. 2022 08; 20 Suppl 16(8):1-12.Clin Adv Hematol Oncol2022-08-01T00:00:002022Cases in the management of polycythemia vera: a patient with progressive leukocytosis.35966045Lovell AR, Jammal N, Bose PTherapeutic advances in hematologySelecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations. Ther Adv Hematol. 2022; 13:20406207221116577.Ther Adv Hematol2022-08-09T00:00:002022Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations.36204692Gerds AT, Bose P, Hobbs GS, Kuykendall AT, Neilson LM, Song J, Klencke B, Harrison CNHemaSphereTreating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world Implications. Hemasphere. 2022 Oct; 6(10):e778.Hemasphere2022-09-30T00:00:002022Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world Implications.36658425Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva MNature medicineComplex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023 01; 29(1):115-126.Nat Med2023-01-19T00:00:002023Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.36075392Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George TI, Gundabolu K, Hexner E, Hobbs GS, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, McMahon B, Mohan SR, Nadiminti KV, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein BL, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward DC, Bergman MA, Hochstetler CJournal of the National Comprehensive Cancer Network : JNCCNMyeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 09; 20(9):1033-1062.J Natl Compr Canc Netw2022-09-01T00:00:002022Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.Authorship 106817717Authorship 10681932Authorship 1068256337070147Vachhani P, Verstovsek S, Bose PExpert opinion on pharmacotherapyCytopenic myelofibrosis: prevalence, relevance, and treatment. Expert Opin Pharmacother. 2023 Jun; 24(8):901-912.Expert Opin Pharmacother2023-04-17T00:00:002023Cytopenic myelofibrosis: prevalence, relevance, and treatment.37102976Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, Turkalj S, Jakobsen NA, Luskin MR, Duose DY, Tidwell RSS, Short NJ, Borthakur G, Kadia TM, Masarova L, Tippett GD, Bose P, Jabbour EJ, Ravandi F, Daver NG, Garcia-Manero G, Kantarjian H, Garcia JS, Vyas P, Takahashi K, Konopleva M, DiNardo CDBlood cancer discoveryA Phase Ib/II Study of Ivosidenib with Venetoclax ? Azacitidine in IDH1-Mutated Myeloid Malignancies. Blood Cancer Discov. 2023 07 05; 4(4):276-293.Blood Cancer Discov2023-07-05T00:00:002023A Phase Ib/II Study of Ivosidenib with Venetoclax ? Azacitidine in IDH1-Mutated Myeloid Malignancies.37081809Pemmaraju N, Bose P, Rampal R, Gerds AT, Fleischman A, Verstovsek SLeukemia & lymphomaTen years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leuk Lymphoma. 2023 06; 64(6):1063-1081.Leuk Lymphoma2023-04-20T00:00:002023Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.Authorship 107089410Authorship 1069590137138019Thompson PA, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N, Wang SA, Jorgensen JL, Kadia TM, Bose P, Pemmaraju N, Short NJ, Wierda WGLeukemiaVenetoclax consolidation in high-risk CLL treated with ibrutinib for =1 year achieves a high rate of undetectable MRD. Leukemia. 2023 07; 37(7):1444-1453.Leukemia2023-05-03T00:00:002023Venetoclax consolidation in high-risk CLL treated with ibrutinib for =1 year achieves a high rate of undetectable MRD.37163478Bose P, Kuykendall AT, Miller C, Kurtin S, Farina K, Harting DM, Mascarenhas JO, Mesa RAExpert opinion on pharmacotherapyMoving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy. Expert Opin Pharmacother. 2023 Jun; 24(9):1091-1100.Expert Opin Pharmacother2023-05-29T00:00:002023Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy.Authorship 10738723Authorship 10724363Authorship 107280820Authorship 1073947237243913Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek SCancerThe role of therapy in the outcome of patients with myelofibrosis. Cancer. 2023 09 15; 129(18):2828-2835.Cancer2023-05-27T00:00:002023The role of therapy in the outcome of patients with myelofibrosis.37422688Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian HJournal of hematology & oncologyA phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol. 2023 07 08; 16(1):73.J Hematol Oncol2023-07-08T00:00:002023A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.37226798Lovell AR, Sawyers J, Bose PExpert opinion on pharmacotherapyAn update on the efficacy of Venetoclax for chronic lymphocytic leukemia. Expert Opin Pharmacother. 2023 May-Aug; 24(11):1307-1316.Expert Opin Pharmacother2023-05-29T00:00:002023An update on the efficacy of Venetoclax for chronic lymphocytic leukemia.37444441Chifotides HT, Verstovsek S, Bose PCancersAssociation of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments. Cancers (Basel). 2023 Jun 24; 15(13).Cancers (Basel)2023-06-24T00:00:002023Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments.Authorship 10779702Authorship 10778854Authorship 10781284Authorship 10778481337635400Kadia TM, Ravandi F, Molica M, Bataller A, Borthakur G, Daver N, Jabbour E, DiNardo CD, Pemmaraju N, Jain N, Ferrajoli A, Ylimaz M, Bose P, Tidwell RS, Marx KR, Rausch CR, Kanagal-Shamanna R, Wang S, Islam R, Champlin R, Shpall E, Konopleva M, Garcia-Manero G, Kantarjian HAmerican journal of hematologyPhase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol. 2023 11; 98(11):1711-1720.Am J Hematol2023-08-27T00:00:002023Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.37729609Bewersdorf JP, How J, Masarova L, Bose P, Pemmaraju N, Mascarenhas J, Rampal RKBloodMoving toward disease modification in polycythemia vera. Blood. 2023 11 30; 142(22):1859-1870.Blood2023-11-30T00:00:002023Moving toward disease modification in polycythemia vera.37699357Masarova L, Bose P, Pemmaraju N, Zhou L, Pierce S, Estrov Z, Kantarjian H, Verstovsek SActa haematologicaRelevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years. Acta Haematol. 2023; 146(6):522-529.Acta Haematol2023-09-12T00:00:002023Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years.37552106Oh ST, Mesa RA, Harrison CN, Bose P, Gerds AT, Gupta V, Scott BL, Kiladjian JJ, Lucchesi A, Kong T, Buckley SA, Tyavanagimatt S, Harder BG, Roman-Torres K, Smith J, Craig AR, Mascarenhas J, Verstovsek SBlood advancesPacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv. 2023 10 10; 7(19):5835-5842.Blood Adv2023-10-10T00:00:002023Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.Authorship 1087756738268448Verstovsek S, Talpaz M, Wadleigh M, Isidori A, Te Boekhorst P, Savona MR, Bose P, Pozdnyakova O, Mesa R, El-Galaly TC, O'Sullivan J, Gamel K, Higgins B, Katakam S, Todorov B, Trunzer K, Harrison CNHaematologicaA randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial. Haematologica. 2024 Jan 25.Haematologica2024-01-25T00:00:002024A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial.Authorship 10883822638320129Gotlib J, Castells M, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S, George TI, Panse J, Alvarez-Twose I, Radia DH, Tashi T, Bulai Livideanu C, Sabato V, Heaney M, Van Daele P, Cerquozzi S, Dybedal I, Reiter A, Pongdee T, Barete S, Ustun C, Schwartz L, Ward BR, Schafhausen P, Vadas P, Bose P, DeAngelo DJ, Rein L, Vachhani P, Triggiani M, Bonadonna P, Rafferty M, Butt NM, Oh ST, Wortmann F, Ungerstedt J, Guilarte M, Taparia M, Kuykendall AT, Arana Yi C, Ogbogu P, Gaudy-Marqueste C, Mattsson M, Shomali W, Giannetti MP, Bidollari I, Lin HM, Sulllivan E, Mar B, Scherber R, Roche M, Akin C, Maurer MNEJM evidenceAvapritinib versus Placebo in Indolent Systemic Mastocytosis. NEJM Evid. 2023 Jun; 2(6):EVIDoa2200339.NEJM Evid2023-05-23T00:00:002023Avapritinib versus Placebo in Indolent Systemic Mastocytosis.Authorship 1088980338341324Vachhani P, Loghavi S, Bose PClinical lymphoma, myeloma & leukemiaSOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2024 Jan 21.Clin Lymphoma Myeloma Leuk2024-01-21T00:00:002024SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis.Authorship 10894173Authorship 1089494638380373Vachhani P, Mascarenhas J, Bose P, Hobbs G, Yacoub A, Palmer JM, Gerds AT, Masarova L, Kuykendall AT, Rampal RK, Mesa R, Verstovsek STherapeutic advances in hematologyInterferons in the treatment of myeloproliferative neoplasms. Ther Adv Hematol. 2024; 15:20406207241229588.Ther Adv Hematol2024-02-19T00:00:002024Interferons in the treatment of myeloproliferative neoplasms.38372648Nwogbo OV, Fang H, Wang W, Xu J, Miranda RN, Bose P, Ok CY, Jorgensen JL, Medeiros LJ, Wang SAAmerican journal of clinical pathologyMulticolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis. Am J Clin Pathol. 2024 Feb 19.Am J Clin Pathol2024-02-19T00:00:002024Multicolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis.Authorship 1090026138441783Bose PCurrent hematologic malignancy reportsManagement of Patients with Early Myelofibrosis: A Discussion of Best Practices. Curr Hematol Malig Rep. 2024 Mar 05.Curr Hematol Malig Rep2024-03-05T00:00:002024Management of Patients with Early Myelofibrosis: A Discussion of Best Practices.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessor